Search

2023 Events calendar

Omixon Blog

Doug Bost became a member of the Scientific Advisory Board for Digital PCR at QIAGEN

10/05/2022

Omixon is entering the field of post-transplant monitoring. To ensure its position in the market our company has entered...

Events

BSHI 2022

22/07/2022

BSHI 2022 | British Society for Histocompatibility and Immunogenetics Conference | 13-14 Sept, 2022, London, UK The...

TESTIMONIALS

Testimonials

“Once again, I congratulate the new version 4.2 of the Twin which is much faster and optimized in processing time and alignment." Romulo Vianna, PhD Rio de Janeiro, State University |UERJ
"It's disappointing sometimes how easily HLA Twin deals with challenging samples like rare alleles. The data is there - you're just convinced!" Alexandre Walencik, Biologiste Médical, Laboratoire HLA - Nantes
“We are using next-generation sequencing techniques to advance patient care at Almac and we know that accurate data and meaningful data interpretation are dependent upon employing the best analysis tools and techniques. Omixon was also the strongest performer in terms of total mutations detected with a 99.14% detection sensitivity in single end mode.”Gavin Oliver, Bioinformatics Team Leader at Almac
"The Holotype HLA method is optimally designed for the service laboratory user and is supported by a clear and easily followed protocol which facilitates method performance. Omixon is an enabling and supportive company who work with you to deliver successful outcomes for your programme rather than sales."Brendan Clarke, HLA Lab Director at Leeds St. James's University Hospital
“Omixon has developed an excellent direct genotyping method from next generation sequencing that addresses the major problems associated with HLA calling. They have developed industry-leading capabilities that we are very pleased to be able to incorporate into the informatics pipeline that powers our interpretation services offerings.”Wolfgang Daum, CEO of Knome
“NGS is rapidly being adopted by clinical and research laboratories worldwide. Easy to use analytical methods and software tools that aid the generation of accurate results are critical for the success of this ground breaking new technology.”Dr Lajos Pusztai,Professor at the University of Texas MD
Anderson Cancer Center
“Best of all, the HLA types reported were fully concordant with data obtained using SBT.”Mike Tayeb, DNA Genotek
"Omixon's Holotype HLA provided greater accuracy with fewer ambiguities, particularly for problematic specimens, than our Sanger SBT procedures."Dr. Pamela Kimball, VCU Health System Authority
"The NGS kit for HLA genotyping, unlike others available in the market, provides complete control of the reactions from the beginning to the end of the technical process, thus providing a higher cost-benefit ratio for the Laboratory. HLA TWIN is the best and most complete HLA genotyping program on the market and has helped us solve many problems in our laboratory routine."Dr. Rafael Cita, Fundação Pio XII Barretos
"Due to the higher throughput and resolution compared to Sanger sequencing, NGS technology improved significantly HLA typing. Omixon`s Holotype HLA workflow and HLA Twin software could be easily implemented in H&I laboratories. Generation of reliable data and ability to extend the typing to additional loci will allow providing better patient care not only in HSCT, but also in organ transplantation."Dr. Milena Ivanova, Bulgarian Bone Marrow Registry